Martin A. Pulè

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis

A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.

Designer small molecule control system based on Minocycline induced disruption of protein-protein interaction.

The paper develops a small-molecule control system using minocycline to disrupt protein-protein interactions for reversible and dose-dependent control of therapeutic applications.

Novel Fas-TNFR chimeras that prevents Fas ligand-mediated kill and signals synergistically to enhance CAR T-cell efficacy

This study identifies Fas-CD40 as a chimeric Fas-TNFR that prevents Fas ligand-mediated kill and enhances CAR T-cell efficacy through synergistic signaling.